Harrow Health, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on the stock and has a $64.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yi Chen has given his Buy rating due to a combination of factors, including Harrow Health’s strong financial performance and promising product growth. Despite a slight miss in revenue projections for the second quarter of 2025, the company achieved a significant year-over-year revenue growth of 30% and exceeded net income expectations, demonstrating robust profitability.
Moreover, Harrow’s product VEVYE has shown impressive market penetration, surpassing competitors and capturing a significant share of the dry eye market. The company’s strategic initiatives, such as expanding its pharmacy network and increasing production capacity, are expected to support continued growth. Additionally, other products like IHEEZO and TRIESENCE are also exhibiting strong growth trajectories, contributing to a positive outlook for Harrow’s future revenue. These factors underpin Yi Chen’s decision to maintain a Buy rating and raise the price target for Harrow Health’s stock.
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HROW in relation to earlier this year.